Mechanisms and consequences of arterial hypertension after renal transplantation

Transplantation

Volumn 72, Issue 6 SUPPL., 2001, Pages

  Koomans, H A ^a   Ligtenberg, G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TACROLIMUS;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BLOOD FLOW; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; SYMPATHETIC NERVE; VASOCONSTRICTION;

EID: 0035960073     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109271-00004     Document Type: Conference Paper

References (26)

1. Hypertension after renal transplantation
2. The epidemic of cardiovascular disease in chronic renal disease: A challenge to the transplant physician
3. Hypertension after renal transplantation
4. Causes of renal allograft loss: Progress in the 1980s, challenges for the 1990s
5. Association of chronic kidney graft failure with recipient blood pressure
6. Arterial hypertension and renal allograft survival
7. Hypertension in patients after renal transplantation
8. Factors associated with arterial hypertension after renal transplantation
9. Hypertension after renal transplantation: Calcium channel or converting enzyme blockade?
10. Sympathetic neural mechanisms of cyclosporine-induced hypertension
11. Acute and chronic effects of cyclosporine on blood pressure, heart rate, and muscle sympathetic nerve activity in healthy volunteers
12. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation
13. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
14. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
15. Immunological and nonimmunological risk factors with tacrolimus and neoral in renal transplant recipients: An interim report
16. Four-year follow-up of the European tacrolimus multicenter renal study
17. Vascular rejection with tacrolimus and potential long-term graft outcome
18. Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up
19. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation
20. Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the U.S. multicenter, randomised, comparative trial
21. Tacrolimus versus cyclosporine in kidney transplantation: Five-year survival results of the U.S. multicenter, randomized, comparative study
22. A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and ciclosporin-microemulsion in renal transplantation
23. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus
24. Conversion to tacrolimus in hyperlipidemic patients
25. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent
26. Cardiovascular disease after renal transplantation